

JCV GCN in a natalizumab-treated MS patient is associated with the p15^{ORF1} capsid gene

Neurology

83, 727-732

DOI: 10.1212/wnl.0000000000000713

Citation Report

#	ARTICLE	IF	CITATIONS
1	New and Old Concepts and Strategies for Progressive Multifocal Leukoencephalopathy. Journal of Multiple Sclerosis, 2014, 02, .	0.1	0
2	Lack of Major Histocompatibility Complex Class I Upregulation and Restrictive Infection by JC Virus Hamper Detection of Neurons by T Lymphocytes in the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2015, 74, 791-803.	1.7	9
3	Novel syndromes associated with JC virus infection of neurons and meningeal cells. Current Opinion in Neurology, 2015, 28, 288-294.	3.6	39
4	Training for a neurology career in a rare disease: The role of cyberconsults. Annals of Neurology, 2015, 77, 738-740.	5.3	8
5	Contrast-Enhancing Lesions within the Spinal Chord Suggests Immune Reconstitution Inflammatory Syndrome (IRIS) in a Patient with Natalizumab Associated Progressive Multifocal Leukoencephalopathy (Natalizumab-PML). Journal of Neuroinfectious Diseases, 2015, s1, .	0.2	0
6	Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy. Neurology: Neuroimmunology and Neuroinflammation, 2015, 2, e177.	6.0	11
7	Natalizumab withdrawal. Reactions Weekly, 2015, 1537, 194-194.	0.0	0
8	JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration. Journal of the Neurological Sciences, 2015, 354, 86-90.	0.6	23
9	Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. Journal of Neurology, 2015, 262, 65-73.	3.6	44
10	Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs, 2015, 29, 759-771.	5.9	16
11	Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311100.	1.9	161
12	John Cunningham Virus-Induced Cerebellar Granular Cell Neuronopathy in a Patient With MS Treated With Natalizumab. Neurographics, 2016, 6, 369-371.	0.2	1
13	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. European Journal of Neurology, 2016, 23, e39-40.	3.3	2
14	Mechanisms of immune escape in central nervous system infection with neurotropic <scp>JC</scp> virus variant. Annals of Neurology, 2016, 79, 404-418.	5.3	40
15	Pitfalls in diagnosing demyelinating cerebellar disease. , 0, , 64-70.		0
17	Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. Current Infectious Disease Reports, 2016, 18, 33.	3.0	13
19	Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence. Journal of Infectious Diseases, 2016, 213, 1436-1443.	4.0	13
20	JC Virus Infects Neurons and Glial Cells in the Hippocampus. Journal of Neuropathology and Experimental Neurology, 2016, 75, 712-717.	1.7	11

#	ARTICLE	IF	CITATIONS
21	Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. Journal of Neurology, 2016, 263, 649-656.	3.6	14
22	Natalizumab granule cell neuronopathy: FDG-PET in diagnosis and immune reconstitution with G-CSF. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e384.	6.0	5
23	JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. Journal of NeuroVirology, 2017, 23, 141-146.	2.1	16
24	Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Advances, 2017, 1, 2041-2045.	5.2	35
25	JC Virus Granule Cell Neuronopathy and Lymphoma. Open Forum Infectious Diseases, 2018, 5, ofy112.	0.9	1
26	Microorganismsâ€™ Footprint in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2018, 12, 466.	3.7	42
27	JC Virus Granule Cell Neuronopathy as AIDS-Presenting Illness. Canadian Journal of Neurological Sciences, 2018, 45, 466-469.	0.5	2
28	Central Nervous System Opportunistic Infections. Seminars in Neurology, 2019, 39, 383-390.	1.4	9
29	Treatment of natalizumabâ€™associated <sc>PML</sc> with filgrastim. Annals of Clinical and Translational Neurology, 2019, 6, 923-931.	3.7	18
30	Cerebellar syndrome in a man treated with natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e546.	6.0	2
31	Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e709.	6.0	7
32	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY ASSOCIATED TO MULTIPLE SCLEROSIS THERAPIES: REVIEW OF THE LITERATURE. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2015, 14, 205-213.	0.1	1
35	Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology, 2022, 22, 344-357.	1.1	1
36	Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world. Expert Opinion on Drug Safety, 0, , 1-8.	2.4	1